Kanwal P.S. Raghav, MBBS, MD

Peer-Reviewed Articles

1. De B, Tran Cao HS, Vauthey JN, Manzar GS, Corrigan KL, Raghav KPS, Lee SS, Tzeng CD, Minsky BD, Smith GL, Holliday EB, Taniguchi CM, Koong AC, Das P, Javle M, Ludmir EB, Koay EJ. Ablative liver radiotherapy for unresected intrahepatic cholangiocarcinoma: Patterns of care and survival in the United States. Cancer 128(13):2529-2539, 2022. e-Pub 2022. PMID: 35417569.
2. Shen C, Tannenbaum D, Horn R, Rogers J, Eng C, Zhou S, Johnson B, Kopetz S, Morris V, Overman M, Parseghian C, Chang GJ, Lopez-Olivo MA, Kanwal R, Ellis LM, Dasari A.. Overall Survival in Phase 3 Clinical Trials and the Surveillance, Epidemiology, and End Results Database in Patients With Metastatic Colorectal Cancer, 1986-2016: A Systematic Review. JAMA Netw Open 5(5):e2213588, 2022. PMID: 35608860.
3. Raghav KP, Stephen B, Karp DD, Piha-Paul SA, Hong DS, Jain D, Chudy Onwugaje DO, Abonofal A, Willett AF, Overman M, Smaglo B, Huey RW, Meric-Bernstam F, Varadhachary GR, Naing A. Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial. J Immunother Cancer 10(5), 2022. PMID: 35618285.
4. Morris V, Kee B, Overman M, Dasari A, Raghav K, Johnson B, Parseghian C, Wolff RA, Garg N, Eng C, Kopetz S. Clinical and pathologic features correlated with rare favorable survival in patients with BRAFV600E mutated colorectal cancer. J Gastrointest Oncol 13(2):647-656, 2022. PMID: 35557581.
5. Taku N, Yi-Qian YN, Chang GJ, Ludmir EB, Raghav KPS, Rodriguez-Bigas MA, Holliday EB, Smith GL, Minsky BD, Overman MJ, Messick C, Boyce-Fappiano D, Koong AC, Skibber JM, Koay EJ, Dasari A, Taniguchi CM, Bednarski BK, Morris VK, Kopetz S, Das P. Benchmarking Outcomes for Definitive Treatment of Young-Onset, Locally Advanced Rectal Cancer. Clin Colorectal Cancer 21(1):e28-e37, 2022. e-Pub 2021. PMID: 34794903.
6. Raghav KP. Sequencing strategies in the management of metastatic colorectal cancer with HER2 amplification. Clin Adv Hematol Oncol 20(2):86-88, 2022. PMID: 35120088.
7. De B, Abu-Gheida I, Patel A, Ng SSW, Zaid M, Thunshelle CP, Elganainy D, Corrigan KL, Rooney MK, Javle M, Raghav K, Lee SS, Vauthey JN, Tzeng CD, Tran Cao HS, Ludmir EB, Minsky BD, Smith GL, Holliday EB, Taniguchi CM, Koong AC, Das P, Koay EJ. Benchmarking Outcomes after Ablative Radiotherapy for Molecularly Characterized Intrahepatic Cholangiocarcinoma. J Pers Med 11(12), 2021. e-Pub 2021. PMID: 34945742.
8. Raghav K, Liu S, Overman MJ, Willett AF, Knafl M, Fu SC, Malpica A, Prasad S, Royal RE, Scally CP, Mansfield PF, Wistuba II, Futreal AP, Maru DM, Solis Soto LM, Parra Cuentas ER, Chen H, Villalobos P, Verma A, Mahvash A, Hwu P, Cortazar P, McKenna E, Yun C, Dervin S, Schulze K, Darbonne WC, Morani AC, Kopetz S, Fournier KF, Woodman SE, Yao JC, Varadhachary GR, Halperin DM. Efficacy, Safety and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma. Cancer Discov 11(11):2738-2747, 2021. e-Pub 2021. PMID: 34261675.
9. Rogers JE, Mizrahi JD, Nogueras Gonzalez GM, Surana R, Shroff RT, Wolff R, Varadhachary GR, Javle MM, Overman M, Raghav K, Pant S. Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imaging. J Gastrointest Oncol 12(5):2268-2274, 2021. PMID: 34790391.
10. Bekaii-Saab TS, Raghav K, Wainberg ZA. How quality of life can inform management decisions in later-line metastatic colorectal cancer: Q&A. Clin Adv Hematol Oncol 19 Suppl 22(10):13-14, 2021. PMID: 35289806.
11. Kanwal Raghav. Quality-of-life concerns in patients with metastatic colorectal cancer. Clin Adv Hematol Oncol 22(10):2-6, 2021. PMID: 35289803.
12. Bekaii-Saab TS, Raghav K, Wainberg ZA.. How quality of life can inform management decisions in later-line metastatic colorectal cancer. Clin Adv Hematol Oncol 22(10):1-16, 2021. PMID: 35289802.
13. Malpica A, Euscher ED, Marques-Piubelli ML, Ferrufino-Schmidt MC, Miranda RN, Sams R, Royal RE, Raghav KPS, Fournier KF, Ramalingam P. Malignant Mesothelioma of the Peritoneum in Women: A Clinicopathologic Study of 164 Cases. Am J Surg Pathol 45(1):45-58, 2021. e-Pub 2020. PMID: 32769428.
14. Kaseb AO, Kappadath SC, Lee SS, Raghav KP, Mohamed YI, Xiao L, Morris JS, Ohaji C, Avritscher R, Odisio BC, Kuban J, Abdelsalam ME, Chasen B, Elsayes KM, Elbanan M, Wolff RA, Yao JC, Mahvash A. A Prospective Phase II Study of Safety and Efficacy of Sorafenib Followed by 90Y Glass Microspheres for Patients with Advanced or Metastatic Hepatocellular Carcinoma. J Hepatocell Carcinoma 8:1129-1145, 2021. e-Pub 2021. PMID: 34527608.
15. Dasari A, Morris VK, Allegra CJ, Atreya C, Benson AB, Boland P, Chung K, Copur MS, Corcoran RB, Deming DA, Dwyer A, Diehn M, Eng C, George TJ, Gollub MJ, Goodwin RA, Hamilton SR, Hechtman JF, Hochster H, Hong TS, Innocenti F, Iqbal A, Jacobs SA, Kennecke HF, Lee JJ, Lieu CH, Lenz HJ, Lindwasser OW, Montagut C, Odisio B, Ou FS, Porter L, Raghav K, Schrag D, Scott AJ, Shi Q, Strickler JH, Venook A, Yaeger R, Yothers G, You YN, Zell JA, Kopetz S. ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper. Nat Rev Clin Oncol 17(12):757-770, 2020. e-Pub 2020. PMID: 32632268.
16. Raghav K, Overman M, Poage GM, Soifer HS, Schnabel CA, Varadhachary GR. Defining a Distinct Immunotherapy Eligible Subset of Patients with Cancer of Unknown Primary Using Gene Expression Profiling with the 92-Gene Assay. Oncologist 25(11):e1807-e1811, 2020. e-Pub 2020. PMID: 32893931.
17. Colina A, Hwang H, Wang H, Katz MHG, Sun R, Lee JE, Thomas J, Tzeng CW, Wolff RA, Raghav K, Overman MJ. Natural history and prognostic factors for localised small bowel adenocarcinoma. ESMO Open 5(6):e000960, 2020. PMID: 33188051.
18. Fujii S, Magliocco AM, Kim J, Okamoto W, Kim JE, Sawada K, Nakamura Y, Kopetz S, Park WY, Tsuchihara K, Kim TW, Raghav K, Yoshino T. International Harmonization of Provisional Diagnostic Criteria for ERBB2-Amplified Metastatic Colorectal Cancer Allowing for Screening by Next-Generation Sequencing Panel. JCO Precis Oncol 4:6-19, 2020. PMID: 35050726.
19. Raghav K, Shen JP, Jácome AA, Guerra JL, Scally CP, Taggart MW, Foo WC, Matamoros A, Shaw KR, Fournier K, Overman MJ, Eng C. Integrated clinico-molecular profiling of appendiceal adenocarcinoma reveals a unique grade-driven entity distinct from colorectal cancer. Br J Cancer 123(8):1262-1270, 2020. e-Pub 2020. PMID: 32733093.
20. Chu JE, Johnson B, Kugathasan L, Morris VK, Raghav K, Swanson L, Lim HJ, Renouf DJ, Gill S, Wolber R, Karsan A, Kopetz S, Schaeffer DF, Loree JM. Population-based screening for BRAFV600E in metastatic colorectal cancer reveals increased prevalence and poor prognosis. Clin Cancer Res 26(17):4599-4605, 2020. e-Pub 2020. PMID: 32571791.
21. Naing A, Meric-Bernstam F, Stephen B, Karp DD, Hajjar J, Rodon Ahnert J, Piha-Paul SA, Colen RR, Jimenez C, Raghav KP, Ferrarotto R, Tu SM, Campbell M, Wang L, Sabir SH, Tapia C, Bernatchez C, Frumovitz M, Tannir N, Ravi V, Khan S, Painter JM, Abonofal A, Gong J, Alshawa A, McQuinn LM, Xu M, Ahmed S, Subbiah V, Hong DS, Pant S, Yap TA, Tsimberidou AM, Dumbrava EEI, Janku F, Fu S, Simon RM, Hess KR, Varadhachary GR, Habra MA. Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer 8(1), 2020. PMID: 32188704.
22. Raghav K, Loree JM, Morris JS, Overman MJ, Yu R, Meric-Bernstam F, Menter D, Korphaisarn K, Kee B, Muranyi A, Singh S, Routbort M, Chen K, Shaw KRM, Katkhuda R, Shanmugam K, Maru D, Fakih M, Kopetz S. Validation of HER2 Amplification as a Predictive Biomarker for Anti-Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer. JCO Precis Oncol 3:1-13, 2019. PMID: 35100667.
23. Huey RW, Makawita S, Xiao L, Matamoros A, Estrella JS, Overman MJ, Varadhachary GR, Raghav K. Sarcomatoid carcinoma presenting as cancers of unknown primary: a clinicopathological portrait. BMC Cancer 19(1):965, 2019. e-Pub 2019. PMID: 31623602.
24. Pedersen KS, Raghav K, Overman MJ. Small Bowel Adenocarcinoma: Etiology, Presentation, and Molecular Alterations. J Natl Compr Canc Netw 17(9):1135-1141, 2019. PMID: 31487680.
25. Shroff RT, Javle MM, Xiao L, Kaseb AO, Varadhachary GR, Wolff RA, Raghav KPS, Iwasaki M, Masci P, Ramanathan RK, Ahn DH, Bekaii-Saab TS, Borad MJ. Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial. JAMA Oncol 5(6):824-830, 2019. e-Pub 2019. PMID: 30998813.
26. Siravegna G, Sartore-Bianchi A, Nagy RJ, Raghav K, Odegaard JI, Lanman RB, Trusolino L, Marsoni S, Siena S, Bardelli A. Plasma HER2 (ERBB2) copy number predicts response to HER2-targeted therapy in metastatic colorectal cancer. Clin Cancer Res 25(10):3046-3053, 2019. e-Pub 2019. PMID: 30808777.
27. Meric-Bernstam F, Johnson AM, Dumbrava EEI, Raghav K, Balaji K, Bhatt M, Murthy RK, Rodon J, Piha-Paul SA. Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer. Clin Cancer Res 25(7):2033-2041, 2019. e-Pub 2018. PMID: 30442682.
28. Meric-Bernstam F, Hurwitz H, Raghav KPS, McWilliams RR, Fakih M, VanderWalde A, Swanton C, Kurzrock R, Burris H, Sweeney C, Bose R, Spigel DR, Beattie MS, Blotner S, Stone A, Schulze K, Cuchelkar V, Hainsworth J. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol 20(4):518-530, 2019. e-Pub 2019. PMID: 30857956.
29. Raghav K, Loree JM, Morris JS, Overman MJ, Yu Ruoxi, Meric-Bernsatm F, Menter D, Korphaisarn K, Kee B, Muranyi A, Singh S, Routbourt M, Chen K, Shaw KR, Katkhuda R, Shanmugam K, Maru D, Fakih M, Kopetz S.. Validation of HER2 Amplification as a Predictive Biomarker for Anti–Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer. JCO Precision Oncology, 2019. e-Pub 2019.
30. Johnson B, Loree JM, Jacome AA, Mendis S, Syed M, Morris Ii VK, Parseghian CM, Dasari A, Pant S, Raymond VM, Vilar E, Overman M, Kee B, Eng C, Raghav K, Kopetz S. Atypical, Non-V600 BRAF Mutations as a Potential Mechanism of Resistance to EGFR Inhibition in Metastatic Colorectal Cancer. JCO Precis Oncol 3, 2019. e-Pub 2019. PMID: 32914034.
31. Dumbrava EEI, Balaji K, Raghav K, Hess K, Javle M, Blum-Murphy M, Ajani J, Kopetz S, Broaddus R, Routbort M, Demirhan M, Zheng X, Pant S, Tsimberidou AM, Subbiah V, Hong DS, Rodon J, Shaw KM, Piha-Paul SA, Meric-Bernstam F. Targeting ERBB2 (HER2) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications. JCO Precis Oncol 3, 2019. e-Pub 2019. PMID: 32923865.
32. Raghav K, Bailey AM, Loree JM, Kopetz S, Holla V, Yap TA, Wang F, Chen K, Salgia R, Hong D. Untying the gordion knot of targeting MET in cancer. Cancer Treat Rev 66:95-103, 2018. e-Pub 2018. PMID: 29730462.
33. Raghav KP, Mahajan S, Yao JC, Hobbs BP, Berry DA, Pentz RD, Tam A, Hong WK, Ellis LM, Abbruzzese J, Overman MJ. From Protocols to Publications: A Study in Selective Reporting of Outcomes in Randomized Trials in Oncology. J Clin Oncol 33(31):3583-90, 2015. e-Pub 2015. PMID: 26304898.
34. Shah MS, Fogelman DR, Raghav KP, Heymach JV, Tran HT, Jiang ZQ, Kopetz S, Daniel CR. Joint prognostic effect of obesity and chronic systemic inflammation in patients with metastatic colorectal cancer. Cancer 121(17):2968-75, 2015. e-Pub 2015. PMID: 25975416.
35. Abdel-Wahab R, Shehata S, Hassan MM, Xiao L, Lee JS, Cheung S, Essa HH, Hassabo HM, Shalaby AS, Mosad E, Raghav K, Rashid A, Wolff RA, Morris JS, Amin HM, Kaseb AO. Validation of an IGF-CTP Scoring System for Assessing Hepatic Reserve in Egyptian Patients with Hepatocellular Carcinoma. Oncotarget 6(25):21193-207, 2015. PMID: 26098859.
36. Chen ZY, Raghav K, Lieu CH, Jiang ZQ, Eng C, Vauthey JN, Chang GJ, Qiao W, Morris J, Hong D, Hoff P, Tran H, Menter DG, Heymach J, Overman M, Kopetz S. Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer. Br J Cancer 112(6):1088-97, 2015. e-Pub 2015. PMID: 25688736.
37. Kaseb AO, Xiao L, Hassan MM, Chae YK, Lee JS, Vauthey JN, Krishnan S, Cheung S, Hassabo HM, Aloia T, Conrad C, Curley SA, Vierling JM, Jalal P, Raghav K, Wallace M, Rashid A, Abbruzzese JL, Wolff RA, Morris JS. Development and validation of insulin-like growth factor-1 score to assess hepatic reserve in hepatocellular carcinoma. J Natl Cancer Inst 106(5), 2014. e-Pub 2014. PMID: 24815863.
38. Raghav K, Overman MJ. Small bowel adenocarcinomas-existing evidence and evolving paradigms. Nat Rev Clin Oncol 10(9):534-44, 2013. e-Pub 2013. PMID: 23897080.
39. Raghav KP, Shetty AV, Kazmi SM, Zhang N, Morris J, Taggart M, Fournier K, Royal R, Mansfield P, Eng C, Wolff RA, Overman MJ. Impact of molecular alterations and targeted therapy in appendiceal adenocarcinomas. Oncologist 18(12):1270-7, 2013. e-Pub 2013. PMID: 24149137.
40. Raghav KP, Wang W, Liu S, Chavez-MacGregor M, Meng X, Hortobagyi GN, Mills GB, Meric-Bernstam F, Blumenschein GR, Gonzalez-Angulo AM. cMET and phospho-cMET protein levels in breast cancers and survival outcomes. Clin Cancer Res 18(8):2269-77, 2012. e-Pub 2012. PMID: 22374333.
41. Raghav KP, Hernandez-Aya LF, Lei X, Chavez-Macgregor M, Meric-Bernstam F, Buchholz TA, Sahin A, Do KA, Hortobagyi GN, Gonzalez-Angulo AM. Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers. Cancer 118(6):1498-506, 2012. e-Pub 2011. PMID: 21837669.
42. Raghav KP, Makkuni P, Figueredo VM. A review of electrocardiography in pulmonary embolism: recognizing pulmonary embolus masquerading as ST-elevation myocardial infarction. Rev Cardiovasc Med 12(3):157-63, 2011. PMID: 22145193.
43. Loree JM, Bailey AM, Johnson AM, Yu Y, Wu W, Bristow CA, Davis JS, Shaw KR, Broaddus R, Banks KC, Lanman RB, Meric-Bernstam F, Overman MJ, Kopetz S, Raghav K. Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer. J Natl Cancer Inst. e-Pub 2018. PMID: 29718453.
44. Zhao Y, Pan Z, Namburi S, Pattison A, Posner A, Balachander S, Paisie CA, Reddi HV, Rueter J, Gill AJ, Fox S, Raghav KPS, Flynn WF, Tothill RW, Li S, Karuturi RKM, George J. CUP-AI-Dx: A tool for inferring cancer tissue of origin and molecular subtype using RNA gene-expression data and artificial intelligence. EBioMedicine 61:103030. e-Pub 2020. PMID: 33039710.
45. Loree JM, Anand S, Dasari A, Unger JM, Gothwal A, Ellis LM, Varadhachary G, Kopetz S, Overman MJ, Raghav K. Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018. JAMA Oncol:e191870. e-Pub 2019. PMID: 31415071.
46. Raghav K, Strickler JH. The Amount of Evidence Needed to Support ERBB2 as a Biomarker for Resistance to EGFR Inhibitors in Metastatic Colorectal Cancer. JAMA Oncol. e-Pub 2019. PMID: 31415062.
47. Willauer AN, Liu Y, Pereira AAL, Lam M, Morris JS, Raghav KPS, Morris VK, Menter D, Broaddus R, Meric-Bernstam F, Hayes-Jordan A, Huh W, Overman MJ, Kopetz S, Loree JM. Clinical and molecular characterization of early-onset colorectal cancer. Cancer. e-Pub 2019. PMID: 30854646.
48. Newhook TE, Overman MJ, Chun YS, Dasari A, Tzeng CD, Cao HST, Raymond V, Parseghian C, Johnson B, Nishioka Y, Kawaguchi Y, Uppal A, Vreeland TJ, Jaimovich A, Arvide EM, Cristo JV, Wei SH, Raghav KP, Morris VK, Lee JE, Kopetz S, Vauthey JN. Prospective Study of Perioperative Circulating Tumor DNA Dynamics in Patients Undergoing Hepatectomy for Colorectal Liver Metastases. Ann Surg. e-Pub 2022. PMID: 35797554.
49. Malpica A, Euscher ED, Marques-Piubelli ML, Miranda RN, Raghav KP, Fournier KF, Ramalingam P. Localized Malignant Peritoneal Mesothelioma (LMPeM) in Women: A Clinicopathologic Study of 18 Cases. Am J Surg Pathol. e-Pub 2022. PMID: 35713639.

Invited Articles

1. Raghav KPS. The role of HER2 amplification testing in metastatic colorectal cancer. Clin Adv Hematol Oncol 16(11):720-722, 2018. PMID: 30543586.
2. Raghav KP, Gonzalez-Angulo AM, Blumenschein GR. Role of HGF/MET axis in resistance of lung cancer to contemporary management. Translational Lung Cancer Research 1(2):179-193, 2012.
3. Raghav KP, Eng C. Role of MET/HGF Axis in Colorectal Cancer: Precepts and Prospects. Colorectal Cancer 1(4):329-341, 2012.
4. Raghav KP, Blumenschein GR. Motesanib and advanced NSCLC: experiences and expectations. Expert Opin Investig Drugs 20(6):859-69, 2011. e-Pub 2011. PMID: 21534718.

Manuals, Teaching Aids, Other Teaching Publications

1. Raghav KP. NEJM Knowledge+. The New England Journal of Medicine, 2014.

Other Articles

1. Pande SA, Raghav K, Mehta S, Babbar G, Kandpal S A woman with a swollen uvula. Cleve Clin J Med 79(9):600-1, 2012. PMID: 22949339.

Editorials

1. Raghav KP, Gonzalez-Angulo AM. Commentary on: Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature. Breast Diseases: A Year Book Quarterly 22(2):156-158, 2011.

Abstracts

1. Raghav KP, Mhadgut H, Lei X, Overman MJ, Ross A, Renato L, Raber M, Varadhacahry GR. Cancer of unknown primary in adolescents and young adults: Clinicopathologic features, prognostic factors, and survival outcomes. ASCO Annual Meeting 2014, 2014.
2. Raghav KP, Amin HM, Wang W, Manyam GC, Broom B, Eng C, Overman MJ, Kopetz S. MET overexpression as a hallmark of the epithelial-mesenchymal transition (EMT) phenotype in colorectal cancer. ASCO Annual Meeting 2013, 2013.
3. Raghav KP, Amin HM, Wang W, Manyam GC, Broom B, Eng C, Overman MJ, Kopetz S. MET overexpression as a hallmark of the epithelial-mesenchymal transition (EMT) phenotype in colorectal cancer. Gastrointestinal Cancer Symposium 2013, 2013.
4. Raghav KP, Kalil K, Ferrarotto R, George B, Eng C, Garrett C, Loyer EM, Hoff PM, Charnsangavej C, Kopetz S, Overman MJ. Bevacizumab reduces the rate of oxaliplatin induced thrombocytopenia and splenomegaly. ASCO Annual Meeting 2012, 2012.
5. Raghav KP, Kazmi SMA, Shetty AV, Taggart M, Fournier K, Royal R, Mansfield P, Eng C, Wolff RA, Overman MJ. Uncovering the clinicopathological and mutational profile of appendiceal adenocarcinomas. Gastrointestinal Cancer Symposium 2012, 2012.
6. Raghav KP, Kalil K, Ferrarotto R, George B, Eng C, Garrett C, Loyer EM, Hoff PM, Charnsangavej C, Kopetz S, Overman MJ. Bevacizumab reduces the rate of oxaliplatin induced thrombocytopenia and splenomegaly. Gastrointestinal Cancer Symposium 2012, 2012.
7. Raghav KP, Wang W, Liu S, Chavez-Mac Gregor M, Meng X, Hortobagyi GN, Mills GB, Meric-Bernstam F, Blumenschein Jr. GR, Gonzalez-Angulo AM. Expression of cMET and phospho-cMET in breast cancers by subtype and impact on survival outcomes. AACR San Antonio Breast Cancer Symposium 2011, 2011.
8. Raghav KP, Liu DD, Matrana MR, Bekele BN, Valero V, Ibrahim NK. Nomogram for predicting development of brain metastasis in patients with inflammatory breast cancer. ASCO Breast Cancer Symposium 2011, 2011.

Book Chapters

1. Raghav KP, Raber M, Varadhachary GR. Cancer of Unknown Primary Site. In: Clinical Decision Support: ONCOLOGY, 2015.
2. Raghav KP, Varadhachary GR. Favorable Subsets Among Cancers of Unknown Primary. In: Textbook of carcinoma of unknown primary. 1. Springer publishing house: Heidelberg, Germany, 2015.
3. Raghav KP, Gilbert MR. Ependymomas. In: Neuro-oncology. First. Blackwell Publishing Ltd: Oxford, UK, 86-94, 2012.
4. Raghav KP, Katz MH, Overman MJ. Cancers of the Small Bowel. In: Textbook of Uncommon Cancer. Fourth. John Wiley & Sons, Inc: Hoboken, NJ, USA, 4441-451, 2012.

Letters to the Editor

1. Overman MJ, Eng C, Raghav K, Matamoros A, Taggart M, Foo WC, Fournier K. Challenges of efficacy assessments in pseudomyxoma peritonea. Oncologist 20: e3-4, 2015.
2. Raghav KP, Taggart MW, Fournier KF, Overman MJ. Is malignant dedifferentiation for mucinous appendiceal neoplasms a valid phenomenon or merely histopathologic ambiguity?. J Am Coll Surg 212: 906; author reply 907, 2011.